This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Jan. 7, 2013 /PRNewswire/ -- Daiichi Sankyo, Co., Ltd. (hereafter, Daiichi Sankyo) and Amplimmune, Inc. (hereafter, Amplimmune) announced today that they have entered into a broad strategic collaboration to develop a new therapeutic protein, AMP-110 (B7-H4 fusion protein). The collaboration will focus on development of AMP-110, a potential immune modulation therapy for autoimmune diseases. This proprietary, first-in-class biologic works by blocking inflammatory T cell differentiation. The parties expect to initiate a Phase 1 clinical study for the compound for the treatment of an autoimmune disease indication in the first half of 2013.
Under the terms of the agreement, Daiichi Sankyo will pay Amplimmune an undisclosed option fee and provide more than
$50 million to reimburse past and planned research and development costs for AMP-110 including funding for future development through a Phase 2 (Proof of Concept Study, hereafter, POC study). Amplimmune also will be eligible to receive additional program milestone payments during the collaboration period. Through the POC study, Daiichi Sankyo will have an exclusive option to acquire the AMP-110 program.
Under the terms of the agreement, Amplimmune will be responsible for manufacturing clinical supplies, regulatory filings and conducting clinical trials through a POC study in autoimmunity. Amplimmune and Daiichi Sankyo expect to collaborate on research to further elucidate the characteristic of AMP-110 and to identify potential biomarkers to predict patient response to AMP-110. If Daiichi Sankyo exercises its exclusive option to acquire the AMP-110 program, then following such acquisition, Daiichi Sankyo will be solely responsible for all future development, manufacturing and commercialization.
"This collaboration strengthens our commitment to working with partners that are at the forefront of science," said
Glenn Gormley, MD, PhD, global head of R&D, senior executive officer of Daiichi Sankyo. "Immune modulation therapy is one of the exciting areas of autoimmune disease research that has the potential to meet an unmet medical need. As a Global Pharma Innovator, identifying and meeting unmet medical needs is an important part of Daiichi Sankyo's mission. We are excited to start with the first trial."